CureVac (CVAC) Stock Price, News & Analysis

Company Overview

CureVac N.V. (NASDAQ: CVAC) is a biotechnology company focused on developing medicines and vaccines based on messenger RNA (mRNA). Its research programs are aimed at using mRNA to instruct cells to produce therapeutic proteins, with applications in infectious diseases, oncology and other medical conditions.

Founded in 2000 and headquartered in Tübingen, Germany, CureVac has developed proprietary mRNA technologies designed to improve the stability, delivery and manufacturing of mRNA-based products. The company has advanced experimental vaccine and therapeutic candidates through preclinical and clinical development, but it does not have a broad portfolio of approved commercial products.

CureVac’s programs have included candidates for COVID-19 and seasonal influenza, as well as cancer immunotherapies and other vaccines. The company has conducted research and clinical activities across Europe and the United States and has pursued development and commercialization collaborations, including a strategic partnership with GSK. Alexander Zehnder served as CureVac’s chief executive officer beginning in 2023.

Key Stats

• Today's Range: $4.66 to $4.66
• 50-Day Range: $4.66 to $4.66
• 52-Week Range: $3.13 to $5.72
• Volume: N/A
• Average Volume: 992,546 shs
• Market Capitalization: $1.05 billion
• P/E Ratio: 6.47
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

CureVac Stock Analysis - MarketRank™

CureVac scored higher than 1% of companies evaluated by MarketBeat, and ranked 879th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

CureVac has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

CureVac has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for CureVac are expected to decrease in the coming year, from $0.72 to ($0.39) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CureVac is 6.47, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.97.

Price to Earnings Ratio vs. Sector

The P/E ratio of CureVac is 6.47, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.64.

Price to Book Value per Share Ratio

CureVac has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CVAC.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CureVac does not currently pay a dividend.

Dividend Growth

CureVac does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for CureVac this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CureVac insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.15% of the stock of CureVac is held by insiders.

Percentage Held by Institutions

17.26% of the stock of CureVac is held by institutions.

Company Calendar

• Last Earnings: 11/24/2025
• Today: 10/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CVAC
• CIK: 1809122
• Web: www.curevac.com
• Phone: 49-70-71988-30
• Fax: 49-7071-9883
• Employees: 880
• Year Founded: 2000

Profitability

• EPS (Trailing Twelve Months): $0.72
• Trailing P/E Ratio: 6.47
• Forward P/E Ratio: 6.47
• P/E Growth: N/A
• Net Income: $175.50 million
• Net Margins: 199.92%
• Pretax Margin: 232.79%
• Return on Equity: -23.03%
• Return on Assets: -19.09%

Debt

• Debt-to-Equity Ratio: 0.03
• Current Ratio: 3.70
• Quick Ratio: 3.69

Sales & Book Value

• Annual Sales: $70.74 million
• Price / Sales: 14.78
• Cash Flow: $0.99 per share
• Price / Cash Flow: 4.73
• Book Value: $3.36 per share
• Price / Book: 1.39

Miscellaneous

• Outstanding Shares: 224,338,000
• Free Float: 219,515,000
• Market Cap: $1.05 billion
• Optionable: No Data
• Beta: 1.77